Trial ID 22101 EMBER-4 | Maryland Oncology Hematology Trial ID 22101 EMBER-4 – Maryland Oncology Hematology

Trial ID 22101 EMBER-4

Trial Information - Phase III

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Protocol ID: J2J-MC-JZLH

Sponsor: Eli Lilly And Company

Status: PENDING OPEN

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Breast

Investigator

Werner MD, Jeanine

Status

PENDING OPEN

Sponsor

Eli Lilly And Company
« Clinical Trails Main

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology